DYAI News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

DY

Mkt Cap

$16.8M

Volume

77.49K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme ProgramDyadic International announced expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program for advanced cellulose processing, building on the success of EN3ZYME™. The program leverages the company's Dapibus™ platform to develop tailored enzyme solutions for pulp biorefining, microcrystalline cellulose, and nanocellulose production. Dyadic plans multiple commercialization pathways including direct sales, partnerships, contract manufacturing, and licensing.GlobeNewswire Inc. · Jul 16, 2026

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ETDyadic International, Inc. (Nasdaq: DYAI), a biotechnology company specializing in precision-engineered proteins and enzymes, will deliver a live interactive presentation at the Skyline Signature Series on May 27, 2026 at 12:00 PM ET. The event will allow investors to ask questions in real time and requires pre-registration.GlobeNewswire Inc. · May 21, 2026

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025Dyadic International, Inc., a biotechnology company focused on large-scale protein manufacturing, announced it will report Q1 2025 financial results and host a corporate update call on May 14, 2025.GlobeNewswire Inc. · May 1, 2025

Industrial Enzymes Global Industry Forecast Report and Company Analysis 2024-2030 Featuring BASF, Advanced Enzyme Technologies, Novozymes, DuPont Danisco, DSM, Kerry, Dyadic, Associated British FoodsThe global industrial enzymes market is expected to grow from $7.03 billion in 2024 to $12.05 billion by 2033, driven by the increasing demand for sustainable manufacturing and the growing use of enzymes in various industries. The report analyzes the market by types, applications, sources, and countries, and provides insights on key players in the industry.GlobeNewswire Inc. · Mar 11, 2025

Dyadic Expands Global Presence with Participation in Key Industry EventsDyadic International, a biotechnology company, announced its participation in several industry events worldwide, including the Developing Countries Vaccine Manufacturers Network (DCVMN) Int'l Annual Meeting 2024, the World Vaccine Congress Europe 2024, and BIO-Europe. The company aims to showcase its proprietary C1 and Dapibus™ technology platforms for producing vaccines, therapeutics, and non-pharmaceutical products.GlobeNewswire Inc. · Oct 9, 2024

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization PartnershipJUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.GlobeNewswire Inc. · Jun 28, 2024

Dyadic to Attend Industry and Investor Events in MayJUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor events during the month of May 2024.GlobeNewswire Inc. · May 8, 2024

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024.GlobeNewswire Inc. · Apr 30, 2024

Dyadic Reports 2023 Full Year Results and Recent Company ProgressJUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the year end 2023 and highlighted recent Company progress.GlobeNewswire Inc. · Mar 28, 2024

Dyadic Announces Change in Board and Management Leadership RolesJUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that Michael Tarnok is stepping down as Chairman of Dyadic’s board of directors (the “Board”) and that current member of the Board Patrick Lucy has been appointed to succeed him, in each case, effective immediately. Mr. Tarnok will continue to serve as a director through the end of his current term, which will end at the Company’s annual meeting in June 2025, at which time he expects to retire. In addition, Dr. Barry Buckland announced that he is retiring and therefore will not stand for re-election at the Company’s annual meeting in June 2024. The Board has decided not to fill the vacancy due to Dr. Buckland’s retirement which will result in a reduction of the size of the Board from seven to six members. Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company.GlobeNewswire Inc. · Mar 28, 2024

DY

DYAIDyadic International, Inc.

DYAI

Pay with—

Available Balance0.00

Your PositionYou don't own any DYAI yet.

Related Tickers

Earnings